NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 850.6 DKK | -2.58% |
|
-4.06% | +21.85% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
05:45pm
- Q1 2024 Earnings Call - London
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
873.1
DKK
Average target price
906.2
DKK
Spread / Average Target
+3.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.85% | 556B | |
| +27.10% | 681B | |
| -4.82% | 361B | |
| +17.23% | 325B | |
| +5.54% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.96% | 157B | |
| +8.63% | 149B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Says Once-Weekly Insulin Icodec Lowered Blood Sugar Levels in Phase 3a Trials
